CELLDEX THERAPEUTICS INC (CLDX)
US15117B2025 - Common Stock
We assign a fundamental rating of 4 out of 10 to CLDX. CLDX was compared to 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CLDX as it has an excellent financial health rating, but there are worries on the profitability. CLDX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CLDX has reported negative net income.
CLDX had a negative operating cash flow in the past year.
In the past 5 years CLDX always reported negative net income.
In the past 5 years CLDX always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -30.37%, CLDX is in the better half of the industry, outperforming 72.77% of the companies in the same industry.
CLDX has a Return On Equity of -32.95%. This is in the better half of the industry: CLDX outperforms 79.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.37% | ||
| ROE | -32.95% | ||
| ROIC | N/A |
ROA(3y)-26.03%
ROA(5y)-28.97%
ROE(3y)-28.07%
ROE(5y)-33.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CLDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLDX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CLDX has been increased compared to 5 years ago.
CLDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CLDX has an Altman-Z score of 35.08. This indicates that CLDX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CLDX (35.08) is better than 95.72% of its industry peers.
CLDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 35.08 |
ROIC/WACCN/A
WACC9.25%
2.3 Liquidity
A Current Ratio of 13.87 indicates that CLDX has no problem at all paying its short term obligations.
The Current ratio of CLDX (13.87) is better than 89.21% of its industry peers.
A Quick Ratio of 13.87 indicates that CLDX has no problem at all paying its short term obligations.
CLDX has a better Quick ratio (13.87) than 89.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.87 | ||
| Quick Ratio | 13.87 |
3. Growth
3.1 Past
The earnings per share for CLDX have decreased strongly by -31.67% in the last year.
CLDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 193.23%.
CLDX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.32% yearly.
EPS 1Y (TTM)-31.67%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-48.21%
Revenue 1Y (TTM)193.23%
Revenue growth 3Y-2.47%
Revenue growth 5Y-6.32%
Revenue growth Q2Q156.58%
3.2 Future
Based on estimates for the next years, CLDX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.91% on average per year.
Based on estimates for the next years, CLDX will show a very strong growth in Revenue. The Revenue will grow by 155.75% on average per year.
EPS Next Y-5.61%
EPS Next 2Y-4.02%
EPS Next 3Y-11.24%
EPS Next 5Y17.91%
Revenue Next Year-10.55%
Revenue Next 2Y-11.51%
Revenue Next 3Y-2.56%
Revenue Next 5Y155.75%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CLDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLDX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CLDX's earnings are expected to decrease with -11.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.02%
EPS Next 3Y-11.24%
5. Dividend
5.1 Amount
CLDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CELLDEX THERAPEUTICS INC
NASDAQ:CLDX (4/24/2024, 7:00:00 PM)
After market: 37.02 0 (0%)37.02
-0.75 (-1.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.38B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.37% | ||
| ROE | -32.95% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.87 | ||
| Quick Ratio | 13.87 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-31.67%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-5.61%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)193.23%
Revenue growth 3Y-2.47%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y